These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9710886)

  • 1. Biologic agents and immunotherapy in rheumatoid arthritis. Progress and perspective.
    Wallis WJ; Furst DE; Strand V; Keystone E
    Rheum Dis Clin North Am; 1998 Aug; 24(3):537-65. PubMed ID: 9710886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of rheumatoid arthritis: etanercept a recent advance.
    Halin J
    J Am Acad Nurse Pract; 2000 Oct; 12(10):433-41; quiz 442-4. PubMed ID: 11930442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early diagnosis and treatment of rheumatoid arthritis for improved outcomes: focus on etanercept, a new biologic response modifier.
    Fleischmann RM
    Clin Ther; 1999 Sep; 21(9):1429-42; discussion 1427-8. PubMed ID: 10509842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etanercept: therapeutic use in patients with rheumatoid arthritis.
    Garrison L; McDonnell ND
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I65-9. PubMed ID: 10577976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological modifier therapy for the treatment of rheumatoid arthritis.
    Jenkins JK; Hardy KJ
    Am J Med Sci; 2002 Apr; 323(4):197-205. PubMed ID: 12003375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences.
    Keiserman M; Codreanu C; Handa R; Xibillé-Friedmann D; Mysler E; Briceño F; Akar S
    Expert Rev Clin Immunol; 2014 Aug; 10(8):1049-57. PubMed ID: 24961616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor inactivation in the management of rheumatoid arthritis.
    Baumgartner SW
    South Med J; 2000 Aug; 93(8):753-9. PubMed ID: 10963503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study.
    Gilbert TD; Smith D; Ollendorf DA
    BMC Musculoskelet Disord; 2004 Oct; 5(1):36. PubMed ID: 15485582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein].
    Fujikawa K; Kawakami A; Eguchi K
    Nihon Rinsho; 2007 Jul; 65(7):1211-7. PubMed ID: 17642234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis].
    Sibilia J
    Med Sci (Paris); 2009 Dec; 25(12):1033-8. PubMed ID: 20035675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
    Feldmann M; Maini RN
    Annu Rev Immunol; 2001; 19():163-96. PubMed ID: 11244034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.
    Fleischmann R; Iqbal I
    Drugs Aging; 2007; 24(3):239-54. PubMed ID: 17362051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab.
    Di Poi E; Perin A; Morassi MP; Del Frate M; Ferraccioli GF; De Vita S
    Clin Exp Rheumatol; 2007; 25(1):85-7. PubMed ID: 17417995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatoid arthritis: new developments in biologic therapy.
    Mahajan A; Sharma R; Khajuria R; Bardi GH; Kapoor B; Gupta V
    J Indian Med Assoc; 2006 Jun; 104(6):327-30. PubMed ID: 17058552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR; Keating GM
    Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.
    Sandborn WJ; Hanauer SB
    Inflamm Bowel Dis; 1999 May; 5(2):119-33. PubMed ID: 10338381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of inflammatory immunologic disease 3. Anti-TNF therapy in rheumatoid arthritis.
    Takeuchi T
    Intern Med; 2007; 46(16):1311-2. PubMed ID: 17704613
    [No Abstract]   [Full Text] [Related]  

  • 19. Etanercept in rheumatoid arthritis.
    Alldred A
    Expert Opin Pharmacother; 2001 Jul; 2(7):1137-48. PubMed ID: 11583065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Paradigm shift in the treatment of rheumatoid arthritis by biologics].
    Tanaka Y
    Rinsho Byori; 2008 Apr; 56(4):309-15. PubMed ID: 18516965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.